Data outside of clinical trials with direct-acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited. Liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) transplant recipients from the Hepatitis C Therapeutic Registry and Research Network database, a multicenter, longitudinal clinical care treatment cohort, treated with direct-acting antiviral regimens between January 1, 2014, and February 15, 2016, were included to assess safety and efficacy. Included were 443 posttransplant patients (KT 5 60, LT 5 347, DLK 5 36); 42% had cirrhosis, and 54% had failed prior antiviral therapy. Most had genotype (GT) 1 (87% with 52% GT1a, 27% GT1b, and 8% GT1 no subtype) and were treated with sofosbuvir (SOF)/ledipasvir 6 ribavirin (85%) followed by SOF 1 daclatasvir 6 ribavirin (9%) and ombitasvir/paritaprevir/ritonavir 1 dasabuvir 6 ribavirin (6%). Rates of sustained virologic response (SVR) at 12 weeks were available on 412 patients, and 395 patients (95.9%) achieved SVR at 12 weeks: 96.6%, 94.5%, and 90.9% among LT, KT, and DLK transplant recipients, respectively. Ribavirin did not influence SVR rates and was more often used in those with higher BMI, higher estimated glomerular filtration rate and lower creatinine. Female gender, baseline albumin 3.5 g/dL, baseline total bilirubin £ 1.2 mg/dL, absence of cirrhosis, and hepatic decompensation predicted SVR at 12 weeks. Six episodes of acute rejection (n 5 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 and after cessation of treatment in 2. Conclusion: In a large prospective observational cohort study, direct-acting antiviral therapy with SOF/ledipasvir, ombitasvir/paritaprevir/ritonavir 1 dasabuvir, and SOF plus daclatasvir was efficacious and safe in LT, KT, and DLK transplant recipients; ribavirin did not influence SVR, and graft rejection was rare. (HEPATOLOGY 2017;66:1090-1101. R ecurrent hepatitis C virus (HCV) is the foremost cause of liver graft loss and death in liver transplant (LT) patients infected with HCV. In patients who have detectable HCV RNA at the time of LT, HCV universally recurs and has an accelerated course with progression to advanced fibrosis in 20%-54% of patients after 5 years post-LT.
R ecurrent hepatitis C virus (HCV) is the foremost cause of liver graft loss and death in liver transplant (LT) patients infected with HCV. In patients who have detectable HCV RNA at the time of LT, HCV universally recurs and has an accelerated course with progression to advanced fibrosis in 20%-54% of patients after 5 years post-LT. (1) Further, extrahepatic complications such as renal disease and increased rate of diabetes mellitus attributable to HCV infection can be encountered. (2) HCV infection is also more prevalent among kidney transplant (KT) recipients than in the US population. (3, 4) HCV in KT recipients accounts for decreased patient and kidney allograft survival, accelerated hepatic fibrosis or cirrhosis, new-onset diabetes after transplantation, cardiovascular disease, sepsis, recurrent glomerulopathy, and de novo posttransplantation glomerular disease. Previously, interferon-based treatments in KT candidates and recipients with HCV were limited by both low response rates and high risk of graft rejection among recipients.
(5-7) Thus, there is an unmet need for new HCV therapies for both LT and KT recipients.
Direct-acting antiviral (DAA) therapies have revolutionized HCV treatment. However, limited data are available on their efficacy and safety in solid organ transplant recipients. Thus, analysis of real-world cohorts of LT and KT recipients may provide valuable insights into the safety and efficacy of these regimens in these cohorts.
Patients and Methods
The Hepatitis C Therapeutic Registry and Research Network (HCV-TARGET) is a consortium of academic (n 5 44) and community (n 5 17) centers that provide medical care and antiviral treatment to HCVinfected patients. Since 2011, patients prescribed HCV treatment as part of routine clinical practice have been enrolled in a longitudinal prospective observational cohort study after offering consent (NIH Clinical Trial NCT01474811). In the current study, data from sequential LT, KT, and dual liver kidney (DLK) transplant recipients treated for chronic HCV were collected prospectively from 37 sites (31 academic and 6 community centers) within a centralized database using standardized source data abstraction as described (8, 9) and managed using Research Electronic Data Capture electronic data capture tools hosted at the University of North Carolina Chapel Hill. Research Electronic Data Capture is a secure, webbased application designed to support data capture for research studies. (10) Patients were eligible if they were 18 or older; LT, KT, or DLK transplant recipients; and treated for HCV with an all-oral regimen with or without ribavirin (RBV). The cohort of patients included in this analysis started treatment no later than February 15, 2016 , in order to allow for adequate follow-up time. This also reflects the time period when sofosbuvir (SOF) 1 ledipasvir (LDV), ombitasvir/paritaprevir/ritonavir 1 dasabuvir (PrOD), and SOF 1 daclatasvir (DAC) with or without RBV were approved and available. We excluded patients treated with simeprevir 1 SOF as they had been previously reported. (11) During the study period, 443 patients meeting these criteria were included (Fig. 1) . In light of the rapidly changing treatment options for HCV, the inclusion window for this cohort was defined a priori without reference to power/sample size calculations to provide a timely description of efficacy and safety of HCV treatment in LT, KT, or DLK transplant recipients in clinical practice settings. The decision to initiate HCV treatment and the selection of the HCV treatment regimen (with or without RBV), the dose of RBV, and the duration of therapy were solely the responsibility of the treating clinician and his or her patient.
MEASUREMENTS
Demographic, clinical, adverse event (AE), and laboratory data were collected throughout the treatment period and the posttreatment follow-up period until the determination of sustained virologic response (SVR) at 12 weeks (SVR12). To account for variability in clinic visits in clinical practice, the window for HCV RNA assessment for SVR was 9 or more weeks following cessation of treatment.
Cirrhosis Assessment
Liver disease stage (cirrhosis or no cirrhosis) was defined at the time of enrollment by biopsy and/or or a combination of clinical, laboratory, histologic, and imaging criteria features. (8, 9) Patients with METAVIR stage 3 fibrosis by liver biopsy were defined as having cirrhosis if they had any of the following: platelet count <140,000/mL; presence of esophageal varices on esophagogastroduodenoscopy; nodular liver, portal hypertension, or ascites by radiologic imaging; noninvasive serum panels such as FibroSURE (Laboratory Corporation of America, Burlington, NC) consistent with stage 4 fibrosis; or liver stiffness measurement by elastography (FibroScan; Echosens North America, Cambridge, MA) consistent with stage 4 fibrosis (kPa 14). In the absence of liver biopsy, cirrhosis was defined as meeting any two of the earlier described nonhistologic criteria.
Hepatic Decompensation
History of hepatic decompensation was defined as evidence of prior or current diagnosis of ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal hemorrhage or baseline concomitant medications with a specific indication for ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal hemorrhage.
Acute Rejection
This was based on serious AE (SAE) reporting only. Additional details on the treatment and outcome of the rejection episode were obtained from the site investigator.
OUTCOMES Efficacy
Treatment efficacy was measured as SVR12, defined as HCV RNA level below the level of quantitation or undetected recorded at least 9 weeks after treatment was discontinued to account for variability of the follow-up at each site. The evaluable population for SVR12 was defined as the group of patients who ended treatment and had final treatment outcome available, including those who were lost to posttreatment follow-up (counted as treatment failures). Patients who discontinued treatment early due to administrative reasons were not included. The per protocol population for SVR12 was patients who completed treatment or discontinued therapy early due to a virological failure and had virological data to assess for SVR12.
Safety
AEs were captured as follows: any event that required an HCV medication dose reduction or discontinuation or the addition of a concomitant medication for management. Anemia was defined as the presence of one of the following: (1) anemia reported as an AE by the investigator; (2) administration of red blood cell growth factors; or (3) blood transfusion. SAEs were any AEs that met the following criteria: (1) required hospitalization or (2) met criteria for expedited reporting per Food and Drug Administration form MEDWATCH 35000. Events of special interest for this study were hepatic decompensation and acute rejection.
ANALYSIS STRATEGY
Demographics and baseline laboratory values were collected and analyzed according to discrete subpopulations of interest (LT, KT, and DLK), and frequencies of AEs were presented by treatment regimen for all patients who started treatment (n 5 443). The unadjusted rates of SVR were calculated for the LT, KT, and DLK groups in the evaluable population (n 5 438) and the per protocol population (n 5 412) (Fig. 1) . Confidence intervals (CIs) of unadjusted rates were calculated using exact binomial methods.
Associations between each baseline covariate of interest and SVR were estimated by multivariable logistic regression analyses with Firth penalized maximum likelihood estimation (adjusted for age and sex) for the LDV/SOF6RBV per protocol population. (12) The set of covariates was selected a priori based on a consensus of clinical expertise and included the bestestablished baseline covariates associated with SVR: sex, age, albumin (<3.5, 3.5 g/dL), platelet count (1,000/lL), total bilirubin (1.2, >1.2 mg/dL), cirrhosis status, history of hepatic decompensation, and history of LT or KT.
Additional Firth multivariable logistic regression analyses adjusted for cirrhosis status were performed on the LT population alone to ascertain the relationship of RBV use to SVR taking into account that RBV is likely to be prescribed more often for cirrhosis.
Analyses were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC).
INFORMED CONSENT
The protocol was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. The independent ethics committee at each participating study center or a central institutional review board approved the protocol if a local institutional review board was not in place. All patients provided written informed consent for their participation. All authors had complete access to the study data and reviewed and approved the final manuscript.
Results

PATIENT POPULATION
Between January 1, 2014, and February 15, 2016, there were 443 patients with chronic HCV who were post-LT (n 5 347; 78%), KT (n 5 60; 14%) or DLK transplant (n 5 36; 8%) treated for HCV (Fig. 1) . The majority of patients were men (n 5 325; 73%), Caucasian (n 5 310; 70%), and younger than 65 years (n 5 310; 70%) ( Table 1) . HCV genotype (GT) 1a and 1b infections were present in 52% and 27%, respectively. A total of 54% (n 5 241) were treatment-experienced, including 28 (6%) with prior exposure to the firstgeneration protease inhibitors telaprevir and boceprevir. Forty-two percent (n 5 184) had cirrhosis, of whom 53% (n 5 97) had a prior episode of hepatic decompensation and 52% (33/63 patients with available Model for End-Stage Liver Disease score) had a pretreatment Model for End-Stage Liver Disease score 10 ( Table 1) .
The baseline clinical and laboratory characteristics were assessed for patients treated with and without RBV (Tables 2A,B) . Among patients who received RBV (n 5 228), 58% were treatment-experienced, 42% had a history of cirrhosis, and 22% had a history of hepatic decompensation. In comparison, among patients treated without RBV (n 5 215), 50% had prior treatment experience, 41% had a history of cirrhosis, and 24% had a history of hepatic decompensation (not shown). Demographic data and baseline laboratory values were similar in both groups except for body mass index (BMI), creatinine and estimated glomerular filtration rate (eGFR). Mean BMI was higher in patients treated with RBV at 28. 8 22, 75 .76) in patients treated without RBV (P 5 0.0006). Although not statistically significant, more patients in the RBV-free group had GT1b (31% versus 24%), while more patients in the RBV-containing group had GT3 (13% versus 4%).
Of the 443 included patients, 378 (85%) were treated with SOF/LDV, of whom 180 were treated with RBV, followed by SOF 1 DAC 6 RBV-containing regimens (9%); 31/39 received RBV and PrOD 6 RBV (6%); 17/26 received RBV. SOF/LDV 6 RBV was used in 86% of LT (n 5 299), 82% of KT (n 5 49), and 92% (n 5 33) of DLK transplant recipients (not shown).
EFFICACY
Per protocol data were available for 412 patients (Fig.  1 ). Of those with per protocol data, 395 patients (95.9%) achieved SVR12, with 96.6% (313/324) among LT recipients, 94.5% (52/55) among KT recipients, and 90.9% (30/33) among DLK transplant recipients ( Fig. 2A-C) . Of the patients who failed to achieve SVR12, the most frequent reason for not achieving SVR was posttreatment relapse. SVR12 rates were similar between LDV/SOF plus RBV versus LDV/SOF alone among LT recipients 97% (95% CI, 93-99) versus 95% (95% CI, 90-98), KT recipients (with and without RBV) 100% (95% CI, 48-100) versus 95% (95% CI, 83-99), and DLK transplant recipients (with and without RBV) 100% (95% CI, 74-100) versus 89% (95% CI, 65-99). Patients with cirrhosis versus noncirrhosis had similar SVR12 rates at 96% (95% CI, 91-98) versus 97% (95% CI, 94-99) among LT recipients and 94% (95% CI, 70-100) versus 95% (95% CI, 83-99) among KT recipients. Among DLK transplant recipients, patients with cirrhosis compared to those without cirrhosis had a numerically lower SVR, 85% (95% CI, 55-98) versus 95% (95% CI, 75-100).
SVR12 rates were similar across GT1a versus 1b at 96% (95% CI, 92-98) versus 99% (95% CI, 94-100) among LT recipients and 93% (95% CI, 76-99) versus 95% (95% CI, 74-100) among KT recipients. Among DLK transplant recipients there was a numeric difference with SVR12 rates of 85% (95% CI, 62-97) in GT1a patients versus 100% (95% CI, 63-100) in GT1b patients. Among LT recipients, 100% (27/27) of GT3-infected patients, 100% (5/5) of GT4-infected patients, and 100% (2/2) of GT6-infected patients achieved SVR12. Similarly, 100% of KT recipients with GT3 (2/2), GT4 (2/2), and GT6 (1/1) achieved SVR12 (not shown).
In the evaluable population (n 5 438) 396 patients (90.4%) achieved SVR12, with 91.3% (314/344) among LT recipients, 89.7% (52/58) among KT recipients, and 83.3% (30/36) among DLK transplant recipients (SVR rates in different subpopulations presented in Supporting Fig. S1A-C) .
PREDICTORS OF SVR12
Associations between covariates of interest and SVR12 among patients with or without solid organ transplant who were treated with LDV/SOF 6 RBV and had per protocol data are shown in Fig. 3 . Receipt of LT and/or KT did not predict SVR12 (odds ratio, 1.1; 95% CI, 0.64-1.99; P 5 0.74) in logistic regression analysis minimally adjusted (for age and sex). Female gender, baseline albumin 3.5 g/dL, baseline total bilirubin 1.2 mg/dL, platelets, and the absence of cirrhosis and hepatic decompensation predicted SVR12 in minimally adjusted regression analyses (Fig. 3) .
Among LT recipients treated with LDV/SOF 6 RBV, RBV use was not associated with SVR12 (odds ratio, 1.54; 95% CI, 0.48-5.16; P 5 0.46) in logistic regression minimally adjusted for cirrhosis (Fig. 4) .
SAFETY AND TOLERABILITY
The overall rate of treatment discontinuation was 2.9%, with AEs being the most common reason (1.6%) ( Table 3) . Among patients receiving LDV/ SOF 6 RBV (n 5 378), PrOD 6 RBV (n 5 26), and DAC/SOF 6 RBV (n 5 39), the frequency of early discontinuation due to AEs was 1.3% (n 5 5), 0% (n 5 0), and 5.1% (n 5 2), respectively. The 1 patient who discontinued therapy early due to lack of efficacy was treated with LDV/SOF 1 RBV. During the study, three deaths were observed, all of which were in LT recipients receiving LDV/SOF and deemed unrelated to HCV treatment. All 3 patients had compensated cirrhosis, and the causes of death were, sepsis, subdural hematoma, and intraventricular hemorrhage. The most common AEs and all SAEs are shown in Table 4 . SAEs were recorded in 45 patients (10%), and the incidence of such events was similar in patients taking or not taking RBV (8% and 13%, respectively). Notable SAEs included infections in 17 patients (4%), anemia in 4 patients (1%), and hepatic encephalopathy in 4 patients (1%). There were 6 patients who experienced rejection during treatment (n 5 4) or after treatment (n 5 2). Two episodes occurred in KT recipients (on SOF1LDV and LDV1SOF1RBV) and 4 in LT recipients (2 on SOF1LDV and LDV1SOF1RBV). Detailed data on the cases of rejection are presented in Supporting Table S1 . Among patients with cirrhosis (n 5 184), SAEs were recorded in 26 (14%).
An analysis of eGFR was done over the DAA treatment period for 12 and 24 weeks in patients treated with RBV and those not treated with RBV, and there were no statistically significant changes observed between the two groups (Supporting Fig. S2A,B) .
In the overall population the most common AEs were fatigue, anemia, headache, nausea, and diarrhea (Table 4) . Fatigue was more common in patients taking RBV (35%) compared with patients taking RBVfree combinations (23%) (not shown). Patients taking RBV were more likely to develop anemia (36%) compared with patients not taking RBV (3%) (not shown). 
Discussion
This large cohort of DAA therapy in solid organ transplant recipients with recurrent hepatitis C from a wide array of transplant programs in the United States provides real-world data on the safety and efficacy of DAA therapy, especially SOF/LDV. In contrast to the clinical trials, (13, 14) this population included patients with mild to severe liver and kidney dysfunction and reflects the challenges seen in clinical practice. Impressively, the SVR12 rates achieved appear to be quite comparable to those in the clinical trials. (12, 13) Among patients with available virological outcomes, sustained viral clearance was achieved in 96% of SOF/LDV 6 RBV-treated patients, 92% of PrOD-treated patients, and 100% of SOF 1 DAC 6 RBV-treated patients. More importantly, treatment discontinuation was very infrequent, highlighting the marked improvement in treatment tolerability in an interferon-free era. These results reinforce the success and ease of HCV therapy in the transplant setting in the current therapeutic environment.
We have previously published on the safety and efficacy of simeprevir and SOF with or without RBV. (9) The current study extends the DAA treatment experience to the drugs approved subsequently. The most frequently used DAA combination in our current cohort was SOF/LDV 6 RBV. Impressively, the successful outcomes noted in our clinical practice experience are similar to what has been observed in clinical trials of carefully selected patients. (13, 14) The unique part of these data is that 122 LT per protocol population recipients were treated with SOF/LDV without RBV, and 116 (95%) achieved SVR. The baseline characteristics of the study population were analyzed for patients treated with and those not treated with RBV, and the only significant differences between the two groups were a lower BMI, a higher baseline creatinine level and a lower eGFR in the RBV-free group. These results present a major difference from the clinical trials in which an RBV-free regimen was not explored. Our large experience, along with a recent observational study with similar responses with an RBV-free regimen of SOF/LDV, (15) should provide confidence in treating LT recipients with an RBV-free regimen, particularly when there are AEs or concerns of tolerability, perhaps not risking efficacy. Nonetheless, we acknowledge limitations to our analysis; the present study was not randomized, and our analysis was based on the per protocol population. A smaller proportion of the transplant recipients were treated with PrOD. In a multicenter phase 3 trial, 34 post-LT patients with recurrent GT1 HCV and METAVIR fibrosis stage F0-F2 were treated with PrOD and weight-based RBV for 24 weeks and achieved an SVR24 rate of 96%. (16) Drug-drug interactions between ritonavir and calcineurin inhibitors are known to exist, and prospective dose adjustments were made in the clinical trial for cyclosporine and tacrolimus. Thus, this regimen is inherently challenging, which is reflected in the limited use of it in clinical practice. The approval of DAC was relatively more recent in the United States, and therefore, this is likely the reason for fewer patients being treated with DAC-based regimens; the SVR rate was high in those treated with DAC/SOF 6 RBV.
Among the LT patients receiving DAA therapy, we examined the factors associated with SVR12. Similar to findings in nontransplant patients, absence of advanced disease, as reflected by additional features of albumin 3.5 g/dL, total bilirubin of 1.2 mg/dL, and adequate platelet count, was consistently associated with better SVR rates. This argues for early treatment of recurrent HCV disease and certainly before the development of cirrhosis. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.
The safety profile observed in this large experience has been impressively good. Forty-two percent of the SOF/LDV 6 RBV cohort had cirrhosis, and 23% had a history of hepatic decompensation; yet the SAE rate in this group was 10%. Most of the SAEs were   FIG. 2 . SVR (per protocol population). In the per protocol population, SVR12 rates with 95% confidence intervals among all patients, patients with cirrhosis, patients without cirrhosis, and LDV/SOF 6 RBV-treated, PrOD 6 RBV-treated, and DAC/ SOF 6 RBV-treated LT recipients (A), KT recipients (B), and DLK transplant recipients (C). Abbreviations: LCL, lower confidence limit; UCL, upper confidence limit.
FIG. 3.
Multivariable analysis of SVR12 among patients with per protocol data treated with LDV/SOF 6 RBV including patients with and without solid organ transplant. Associations between every baseline covariate and SVR12 were estimated with logistic regression using Firth penalized maximum likelihood estimation of the effect of a covariate of interest with adjustment for age and sex. *Covariates treated in this manner. Abbreviations: LCL, lower confidence limit; OR, odds ratio; Nobs, number observed; TBIL, total bilirubin; UCL, upper confidence limit.
FIG. 4.
Multivariable analysis of SVR12 among LT patients with per protocol data treated with LDV/SOF 6 RBV. KT patients were excluded from the analysis. Associations between every baseline covariate and SVR12 were estimated with logistic regression using Firth penalized maximum likelihood estimation. *Minimally adjusted for cirrhosis status. Abbreviations: LCL, lower confidence limit; OR, odds ratio; Nobs, number observed; TBIL, total bilirubin; UCL, upper confidence limit.
infection, a complication well recognized to occur in those with cirrhosis. The rate of discontinuation of therapy due to an AE was 1.6%, which is a reflection of the excellent tolerability of these regimens.
Traditionally, rejection in the graft had been seen in the interferon era, and it had been suggested that this was due to either the immunomodulatory effects of interferon or improved hepatic function, after successful eradication of the virus, and better pharmacokinetics of the calcineurin inhibitors leading to lower trough levels. (17) Acute cellular rejection historically, based on a recent Scientific Registry of Transplant Recipients data analysis, independent of HCV with or without therapy, occurred in approximately 10.9% of LT recipients within the first 6 months of transplant and in 2.3% beyond 1 year of LT (18) ; and in this experience rejection requiring treatment was reported in 6/443 (1.4%) patients. While it is difficult to attribute causality to HCV therapy, it is nevertheless important to be vigilant of such an occurrence, particularly when there might be drug-drug interactions as with the PrOD regimen. One strategy to consider is of delaying treatment for about 3-6 months after transplant as most rejection episodes after transplant occur early on in the posttransplant period.
The safety of DAAs in patients with renal impairment is a topic of considerable interest and clinical relevance as few patients in phase 3 clinical trials with severe kidney function impairment were enrolled. It is known that SOF and its circulating metabolite GS-331007 are cleared renally, and there is a concern of SOF use in those with an eGFR <30 mL/minute. (19) As a consequence, international guidelines and product labeling state that no formal recommendation on dosing of SOF can be made in those with eGFR <30 mL/minute. Only 6% of patients enrolled in the current analysis of post-LT, post-KT, and post-DLK populations had an eGFR 30 mL/minute, and thus, meaningful data on the impact of HCV therapy on renal function in those with severely impaired renal function could not be determined. The real-world experience of treatment of KT patients is understandably more limited than in the post-LT population. (20) (21) (22) Beinhardt and colleagues recently demonstrated safety and efficacy of DAA regimens in 25 patients (24 on a SOF-containing regimen), of whom 10 were on hemodialysis, 8 were KT recipients, 7 were DLK recipients with stable kidney function on treatment, and 96% achieved SVR12. (20) Sawinski and colleagues demonstrated excellent efficacy and safety of DAAs in a group of 20 consecutive KT recipients, of whom 88% were GT1, 50% had biopsy-proven METAVIR F3 or F4 fibrosis, and 60% had failed interferon-based therapy. DAA therapy was initiated a median of 888 days after renal transplantation, and there was a 100% rate of SVR12; the most commonly used regimen was SOF plus simeprevir, and fewer than half of patients required calcineurin inhibitor dose adjustment during treatment. (22) Kamar and colleagues similarly performed a pilot study to assess efficacy and safety of SOF-based regimens in 25 KT recipients (76% GT1), with rapid virological response achieved in 88% and SVR12 in 100% of patients. A decrease in calcineurin inhibitor levels was noted after HCV clearance. No AEs were observed. (21) The HCV-TARGET experience is the largest thus far, with 347 LT recipients, 60 KT recipients, and 36 DLK transplant recipients where HCV therapy was highly efficacious and well tolerated independent of GT1 subtype and presence or absence of cirrhosis; a good number of patients were treated with an RBV-free regimen.
In summary, in this large clinical practice, LT, KT, and DLK patients across a spectrum of liver and kidney disease severity achieved high rates of SVR12 with DAA therapy. SOF/LDV was the most commonly used regimen, and although RBV is recommended by guidelines for LT and DLK transplant recipients, nearly half of the patients were treated without RBV and achieved comparable SVR12 rates. This suggests that RBV may not be essential for all transplant recipients. While treatment is safe and extremely well tolerated, acute rejection can still occur, albeit infrequently, necessitating a thoughtful approach to the timing of treatment and careful monitoring during treatment.
